Endometrial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)

The treatment landscape for endometrial carcinoma is undergoing rapid transformation, fueled by the increasing use of immune checkpoint inhibitors and advances in molecular classification. In the first-line advanced setting, Merck’s pembrolizumab and GSK’s dostarlimab in combination with carboplatin + paclitaxel are the preferred regimens, while AstraZeneca’s durvalumab is primarily used in patients with dMMR tumors. For HER2-positive disease, biomarker-directed options include trastuzumab with carboplatin + paclitaxel and Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan. The expanding role of immune checkpoint inhibitors in the first line is also reshaping management in the recurrent setting. Meanwhile, late-phase trials of novel antibody-drug conjugates aim to refine patient segmentation and will broaden treatment choices in later lines. These advancements will accelerate the market growth and diversify therapeutic options during the 2024–2034 forecast period.

Questions answered

• How are immune checkpoint inhibitors transforming the treatment landscape for advanced endometrial carcinoma, and how are they expected to influence the drug-treatment rates over time?
• How will biomarker-driven therapies influence treatment decisions and expand drug-treatable patient populations?
• Which are the most promising emerging therapies in the late-phase pipeline? What uptake and patient shares can these agents be expected to secure?
• What are the key drivers and constraints in the endometrial carcinoma market, and how will this market evolve over the forecast period?

Geography: United States, EU5, Japan

Primary research: 19 country-specific interviews with thought-leading medical oncologists / gynaecologic oncologists, supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed incidence of endometrial carcinoma by country and disease stage; clinically and market-relevant drug-treatable populations.

Forecast: 10-year, annualized, drug-level sales and patient share of key endometrial carcinoma therapies through 2034 segmented by brands / generics and epidemiological subpopulations.

Drug treatments: Coverage of key current and late-phase emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.